ClinicalTrials.gg

Program

Sustained-Release Gemcitabine-Docetaxel NDV-01

Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms · Urologic Neoplasms, led by Relmada Therapeutics.

Furthest: phase 3, since Dec 29, 20253 company-led studies, 1 open or runningNext primary completion: Dec 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Relmada Therapeutics31 open or runningphase 3since Dec 29, 2025Dec 29, 2025Dec 2029phase 3 · NCT07464145

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 29, 2025First study: phase 3 study in NeoplasmsFirst studyNCT07313891
  2. Jan 13, 2026Phase 3 study in NeoplasmsNCT07342517
  3. Mar 2, 2026Phase 3 study in NeoplasmsNCT07464145 · 393 planned

Ahead

  1. Dec 2029Primary completion: phase 3 study in NeoplasmsNCT07464145

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07464145Neoplasms3Not yet recruitingDec 2029393
NCT07342517Neoplasms3WithdrawnJun 30, 20270
NCT07313891Neoplasms3WithdrawnSep 1, 20290

How it is read

Names in the registry

  • “NDV-01 (sustained-release gemcitabine-docetaxel)”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.